+41.4%
NFLX vs GSK
+67.2%
-25.8%
-53.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.1% | -0.6% | -0.5% | -1.0% |
| 7D | -0.3% | +5.2% | -5.4% | -0.8% |
| 30D | -10.0% | +10.2% | -20.2% | -10.9% |
| 3M | -17.1% | -0.9% | -16.2% | -17.1% |
| 6M | -27.7% | +3.5% | -31.2% | -27.9% |
| YTD | -32.5% | +7.2% | -39.8% | -32.5% |
| 1Y | -43.5% | +12.0% | -55.5% | -43.6% |
| 3Y | +41.4% | +67.3% | -25.9% | +45.5% |
| All | +41.4% | +67.2% | -25.8% | +45.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling